Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methotrexate
Drug ID BADD_D01418
Description Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis.[A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division.[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.[L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198]
Indications and Usage Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150,L10457] Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180]
Marketing Status approved
ATC Code L01BA01; L04AX03
DrugBank ID DB00563
KEGG ID D00142
MeSH ID D008727
PubChem ID 126941
TTD Drug ID D0SV8E
NDC Product Code 49452-4601; 51927-1565; 0143-9516; 51285-369; 59137-510; 61703-408; 66220-807; 66220-822; 69238-1423; 12780-0491; 46014-1023; 51407-121; 54436-025; 61703-350; 66220-810; 71335-1772; 46014-1005; 16729-277; 0143-9518; 0143-9519; 50268-527; 51079-670; 70771-1058; 70518-1398; 0555-0572; 0143-9367; 66220-815; 70518-3263; 0703-3675; 58623-0040; 0143-9517; 0143-9830; 54436-020; 59137-505; 59137-535; 59137-540; 0378-0014; 66220-825; 42291-505; 47781-482; 52652-2001; 54436-012; 54436-015; 54436-022; 59137-515; 59137-550; 66220-812; 66220-820; 71335-1118; 50090-5457; 51285-368; 54436-010; 59137-520; 59651-182; 68382-775; 0703-3671; 16729-486; 51285-366; 51285-367; 59137-525; 59137-530; 61703-124; 46014-1133; 63660-0006; 66220-817; 70518-3672; 0703-3678; 0904-7141; 54436-017
UNII YL5FZ2Y5U1
Synonyms Methotrexate | Amethopterin | Methotrexate, (D)-Isomer | Methotrexate, (DL)-Isomer | Mexate | Methotrexate Sodium | Sodium, Methotrexate | Methotrexate, Sodium Salt | Methotrexate, Disodium Salt | Methotrexate Hydrate | Hydrate, Methotrexate | Methotrexate, Dicesium Salt | Dicesium Salt Methotrexate
Chemical Information
Molecular Formula C20H22N8O5
CAS Registry Number 59-05-2
SMILES CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary pain22.12.01.0100.000250%Not Available
Portal fibrosis24.08.06.004; 09.01.04.0080.000227%Not Available
Disease susceptibility08.01.03.066--Not Available
Graft versus host disease in gastrointestinal tract10.02.01.059; 07.11.01.027; 12.02.09.0280.000227%Not Available
Lower respiratory tract congestion22.12.01.0040.000387%Not Available
Gastrointestinal wall thickening07.01.06.0320.000114%Not Available
Fine motor skill dysfunction17.01.02.0200.001023%Not Available
Steatohepatitis14.08.04.020; 09.01.07.0240.000171%Not Available
Gluten sensitivity14.02.01.008; 10.01.01.031; 07.17.01.009--Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.035--Not Available
Soft tissue swelling15.03.02.0200.000387%Not Available
Vein rupture24.03.02.032; 12.01.11.011--Not Available
Tongue discomfort07.14.02.019--Not Available
Administration site bruise24.07.06.025; 23.03.11.023; 12.07.04.016; 08.02.04.0160.000387%Not Available
Adrenal adenoma16.37.03.002; 05.01.04.0090.000114%Not Available
Anal stenosis07.13.05.004--
Arthritis enteropathic15.01.01.017; 10.02.01.069; 07.08.03.019--Not Available
Aversion19.05.01.0230.000250%Not Available
Behaviour disorder19.01.01.005--Not Available
Bell's palsy17.04.03.011--Not Available
Corneal toxicity12.03.01.061; 06.11.03.0030.000114%Not Available
Cutaneous amyloidosis23.07.04.036; 10.02.05.007--Not Available
Discharge08.01.03.086--Not Available
Drug effect less than expected08.06.01.036--Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.021002%Not Available
Dysbiosis12.02.05.053; 07.11.01.0340.004446%Not Available
Dyschromatopsia06.02.09.003--Not Available
Elbow deformity15.10.03.012--Not Available
Enterocolonic fistula07.11.05.019--Not Available
Epstein Barr virus positive mucocutaneous ulcer16.21.02.006; 11.05.10.009; 07.05.06.010; 01.13.02.006; 23.07.03.0240.002104%Not Available
The 34th Page    First    Pre   34 35 36 37    Next   Last    Total 37 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene